Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) FCF Margin (2020 - 2023)

Historic FCF Margin for Gain Therapeutics (GANX) over the last 4 years, with Q1 2023 value amounting to 7663.03%.

  • Gain Therapeutics' FCF Margin fell 22077200.0% to 7663.03% in Q1 2023 from the same period last year, while for Dec 2023 it was 34217.53%, marking a year-over-year decrease of 236463300.0%. This contributed to the annual value of 34217.53% for FY2023, which is 236463300.0% down from last year.
  • Latest data reveals that Gain Therapeutics reported FCF Margin of 7663.03% as of Q1 2023, which was down 22077200.0% from 5358.05% recorded in Q2 2022.
  • Gain Therapeutics' 5-year FCF Margin high stood at 3632.9% for Q2 2021, and its period low was 53869.71% during Q1 2021.
  • Moreover, its 4-year median value for FCF Margin was 8134.8% (2021), whereas its average is 12501.52%.
  • As far as peak fluctuations go, Gain Therapeutics' FCF Margin crashed by -425148000bps in 2021, and later soared by 484144000bps in 2022.
  • Gain Therapeutics' FCF Margin (Quarter) stood at 14473.88% in 2020, then soared by 34bps to 9621.98% in 2021, then soared by 44bps to 5358.05% in 2022, then crashed by -43bps to 7663.03% in 2023.
  • Its FCF Margin stands at 7663.03% for Q1 2023, versus 5358.05% for Q2 2022 and 5455.31% for Q1 2022.